For licensed healthcare professionals. The protocol figures below are drawn from published labeling and peer-reviewed literature for educational reference. They are not a prescription, not a recommendation, and not a substitute for the dispensing pharmacy's labeling or your own clinical judgment.

GH Secretagogue

Hexarelin

WADA prohibited

Potent GH secretagogue with longer-lasting effect than GHRP-6; receptor desensitization can occur with chronic high doses.

At a glance

Common vial size: 5 mg
Reference dose: 100 mcg
Frequency: 1–2× daily

Reference titration protocol

100 mcg, 1–2× daily; cycle to avoid desensitization.

Reference titration ladder for Hexarelin
Step	Dose	Duration	Administrations / week
1	100 mcg	4 weeks	14×

Reconstitution example

A 5 mg vial reconstituted with 2 mL of bacteriostatic water yields 2.5 mg/mL. Confirm the diluent and volume against the labeling that ships with the vial.

Open this configuration in the calculator

Clinical notes

Tachyphylaxis reported with continuous high-dose use — cycle dosing

Available formulations

Presentations carried across the VitaRelay pharmacy network, including 503A compounded, 503B outsourcing facility, and research & development sourcing. Pricing and state-level availability are shown to verified accounts only.

Lyophilized PowderRUO

Often used with

Compounds commonly discussed alongside Hexarelin in published protocols and prescriber requests. Listed for reference only — not a clinical recommendation, and not a suggestion to co-administer.

Pricing and ordering are for verified accounts

VitaRelay serves licensed practices, prescribers, and pharmacies. Catalog pricing, availability by state, and ordering are available after your account is verified.

Also in GH Secretagogue

Sermorelin

GHRH 1-29 analog that stimulates pulsatile endogenous GH release. Historically FDA-approved (Geref, withdrawn 2008); now compounded.

Tesamorelin

Stabilized GHRH analog FDA-approved for HIV-associated lipodystrophy. Often compounded with ipamorelin in anti-aging protocols.

Ipamorelin

Selective ghrelin/GHS-R agonist that triggers pulsatile GH release with minimal cortisol or prolactin impact. WADA-prohibited.

CJC-1295 (no DAC)

GHRH analog often stacked with ipamorelin to amplify endogenous GH pulses. WADA-prohibited.

GHRP-2

Synthetic hexapeptide ghrelin-receptor agonist. Stronger GH release than GHRP-6 with less appetite stimulation.

GHRP-6

Ghrelin-receptor agonist with marked appetite-stimulant effect. Often stacked with a GHRH (sermorelin or CJC-1295).

Educational information for licensed healthcare professionals

The material on this page is general educational information intended for licensed healthcare professionals and their clinical staff. It is not medical advice, is not a substitute for professional judgment, and does not establish a provider-patient relationship. Nothing here should be read as a recommendation for, or endorsement of, any specific therapy, product, or course of treatment. Compounded preparations must be handled in accordance with applicable federal and state law, the dispensing pharmacy's labeling, and your own institutional policies. All clinical decisions — including product selection, preparation, dosing, and administration — remain the sole responsibility of the treating licensed practitioner.

VitaRelay is a technology and logistics network. We are not a pharmacy, prescriber, or distributor. See our Terms of Service and service availability for details.